Eisaku Iwanaga, Tomoko Nanri, Naofumi Matsuno, Toshiro Kawakita, Hiroaki Mitsuya, Norio Asou. A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia. haematol [Internet]. 2009Feb.27 [cited 2024May7];94(3):433-5. Available from: https://haematologica.org/article/view/5208